Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 18, 2026.

The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer

Yi Shi, David J. Riese, Jianzhong Shen

Frontiers in Pharmacology · 2020 · Review · CC BY

doi:10.3389/fphar.2020.574667

Abstract

Chemokines are a family of small, secreted cytokines which regulate a variety of cell functions. The C-X-C motif chemokine ligand 12 (CXCL12) binds to C-X-C chemokine receptor type 4 (CXCR4) and C-X-C chemokine receptor type 7 (CXCR7). The interaction of CXCL12 and its receptors subsequently induces downstream signaling pathways with broad effects on chemotaxis, cell proliferation, migration, and gene expression. Accumulating evidence suggests that the CXCL12/CXCR4/CXCR7 axis plays a pivotal role in tumor development, survival, angiogenesis, metastasis, and tumor microenvironment. In addition, this chemokine axis promotes chemoresistance in cancer therapy via complex crosstalk with other pathways. Multiple small molecules targeting CXCR4/CXCR7 have been developed and used for preclinical and clinical cancer treatment. In this review, we describe the roles of the CXCL12/CXCR4/CXCR7 axis in cancer progression and summarize strategies to develop novel targeted cancer therapies.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 18, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Chemokines are small secreted peptides with molecular weights in the range of 8–12 kD. They are best known for their roles in the mediation of immune cell recruitment. Subsequently, they were reported to play essential roles in various pathological conditions, including inflammation, atherosclerosis, hematopoiesis, and cancer. Based on the arrangement of the two cysteine residues near the amino terminus, chemokines can be classified into four subfamilies (CC, CXC, CX3C, and C). Chemokines exert their function by binding to seven-transmembrane- spanning G protein-coupled cell-surface receptors. Named by their endogenous ligand (chemokines), chemokine receptors are grouped into two subfamilies: conventional chemokine receptors (CCKRs) and atypical chemokine receptors (ACKRs). Chemokines binding to CCKRs would induce a conformational change in the receptor, leading to intracellular signal transduction. However, ACKRs do not couple to many signal transduction pathways, which are considered as scavengers for chemokines.

Stromal cell-derived factor-1 (SDF-1), which is also referred to as CXCL12, is a homeostatic CXC chemokine that possesses seven different isoforms. It is secreted in a wide range of different tissues by stromal cells, fibroblasts, and epithelial cells, regulating hematopoietic cell trafficking and secondary lymphoid tissue architecture. Growing evidence has shown regulatory roles of the tumor stromal cell interactions in tumor initiation and progression. CXCL12 and its receptors, CXCR4 and CXCR7, have been identified as the key factors in tumor development and metastasis Ovarian epithelial tumor cells express high levels of CXCL12. CXCL12 induces signaling via the AKT and ERK pathways, stimulating ovarian cancer cell growth in vitro. Similarly, the expression of CXCL12 is associated with pathological features and clinical outcomes in human breast cancer. Moreover, CXCL12 is expressed at high levels in bladder cancer, gastric cancer, hepatocellular carcinoma, prostate cancer, lung cancer, and many other human tumors. However, the exact functions of CXCL12 in most cancers are yet to be fully elucidated.

CXCR4, also known as fusin, is a highly conserved seven transmembrane-spanning G-protein coupled receptor. It consists of 352 amino acid residues, including an amino (N)-terminus, three extracellular and intracellular loops, 7 TM helices, and a carboxyl (C)-terminus. CXCL12 is the only confirmed chemokine that binds to CXCR4, although studies implicate other factors activate this receptor, such as macrophage migration inhibitory factor (MIF) and extracellular ubiquitins. CXCR4 was initially found to function as a co-receptor required for entry of T-tropic (X4) HIV viruses that target CD4-positive T cells. Later, CXCR4 has been discovered strongly expressed in multiple types of cancers, including breast cancer, kidney cancer, ovarian cancer, thyroid cancer, prostate cancer, lung cancer, colon cancer, and thymoma. Along with its ligand CXCL12, CXCR4 controls the transduction of different downstream signaling pathways that are profoundly involved in tumor cell survival, proliferation, and migration. In addition, increasing evidence showed that CXCR4 not only plays a marked role in cancer metastasis but also in cancer stem cells.

CXCR7, also named atypical chemokine receptor 3 (ACKR3), is a seven-transmembrane G-protein coupled receptor. It was originally cloned from a dog thyroid cDNA library and named receptor dog cDNA 1 (RDC-1). CXCR7 was initially presumed to be a receptor for vasoactive intestinal peptide (VIP) and calcitonin gene-related peptide 1 (CGRP1), but subsequent studies did not confirm this. CXCR4 has been thought to be the only receptor for CXCL12. However, CXCR7 was identified to be a higher-affinity receptor for CXCL12 than is CXCR4 in 2005. CXCR7 has been regarded as a scavenger receptor for CXCL12 in some studies, while other evidence suggested that CXCR7 could induce intracellular signaling associated with CXCR4. Current studies have found CXCR7 is present in diverse tumor cell lines, including breast cancer, cervical carcinoma, glioma, and pancreatic cancer. Additionally, the expression of CXCR7 is extensively high in the endothelial cells of tumor tissues. Another research group addressed a correlation between the expression of CXCR7 and enhanced adhesive/invasive activities in prostate cancer. These specific features suggest that CXCR7 is closely related to tumor progression.

This review summarizes the downstream cell signaling transduction of CXCL12/CXCR4/CXCR7 axis (abbreviation: CXCL12 axis) and the role of CXCL12 axis in tumor progression, growth, survival, angiogenesis, metastasis, and chemoresistance. We also emphasize the therapeutic targeting of the CXCL12 axis for cancer treatment.

C-X-C Motif Chemokine Ligand 12 Axis Signal Transduction

CXCL12/CXCR4/CXCR7 can stimulate diversified downstream signaling pathways that regulate chemotaxis, gene transcription, cell survival, and proliferation. Figure 1 presents the principal signaling pathways thought to be involved in CXCL12 signal transduction. The precise transduction may differ between cell types as some features might be tissue-dependent.

CXCL12 binding to CXCR4 promotes a three-dimensional conformation change and initiates the exchange from GTP to GDP, leading to the dissociation of Gα subunit from Gβ/Gγ dimer. The dissociated Gβ/Gγ dimer is capable of activating phospholipase C (PLC)-β, which catalyzes the hydrolysis of phosphatidylinositol (4,5)-bisphosphate (PIP2) into two secondary messengers, inositol (1,4,5)- trisphosphate (IP3) and diacylglycerol (DAG). Upon binding with IP3, IP3 receptor (IP3R) triggers the release of calcium from intracellular stores into the cytoplasm. DAG promotes the activation of protein kinase C (PKC) and mitogen-activated protein kinase (MAPK), which contributes to chemotaxis. The Gβ/Gγ dimer is additionally involved in Ras activation of the MAPK/ERK cascade, inducing profound consequences for gene expression and cell cycle progression. Based on the coupled Gα subunits, diverse GPCR signaling pathways can be classified into four families: Gαs, Gαi, Gαq, and Gα12. At first, CXCR4 was classified as a Gαi-protein-coupled receptor. The activation of Gαi subunits inhibits adenyl cyclase, which catalyzes 5′adenosine triphosphate into cyclic adenosine monophosphate (cAMP), thereby regulating other downstream effectors. Either the Gβ/Gγ dimer or the Gαi subunit can activate phosphoinositide-3 kinase (PI3K), leading to phosphorylation of multiple focal adhesion proteins and contributing to cell migration. By generating phosphatidylinositol (3,4,5)- triphosphate, PI3K can trigger the activation of the serine-threonine kinase AKT, thus stimulating the downstream transcription factor nuclear factor- κB (NF-κB) and mTOR pathways, which play key roles in tumor cell survival and proliferation. In addition, Gαi is in some contexts necessary for Rac activation. Despite the well-characterized coupling to Gαi, CXCR4 can also transduce signal through other Gα proteins, such as Gαq and Gα12/13. CXCR4 coupled to Gαq can couple to downstream events via PLC-β, which leads to increased IP3 synthesis and PKC signaling. CXCR4 stimulation of Gα12/13 can also stimulate Bruton’s tyrosine kinase, which inhibits Fas-mediated apoptosis. Furthermore, Gα12/13 is required as a direct activator of Rho through the modulation of Rho-guanine nucleotide exchange factors. CXCR4 signaling is modulated by receptor internalization and lysosomal degradation. Following CXCL12 binding, the intracellular C-terminus of CXCR4 is rapidly phosphorylated at serine sites by G-protein coupled receptor kinases (GRKs), resulting in recruitment of β-arrestin and clathrin-mediated endocytosis. β-arrestin prevents the CXCR4 from coupling with G proteins and targets them for lysosomal degradation.

Initially, CXCR7 was characterized as a scavenger or decoy receptor for CXCL12 due to the absence of typical intracellular responses (such as intracellular calcium mobilization or modulation of adenylyl cyclase activity) after CXCL12 binding. Moreover, unlike CXCR4 internalization, CXCR7 internalization occurs even in the absence of ligand binding and does not result in receptor degradation. Like CXCR4, CXCR7 can activate numerous intracellular signaling pathways, especially the AKT and MAPK pathways, via G-proteins or by β-arrestin. CXCR4 and CXCR7 can each form homo- and heterodimers. The formation of heterodimers enhances CXCL12-dependent intracellular calcium mobilization and ERK1/2 phosphorylation, yet blocks CXCR4 coupling to G protein complexes. Therefore, CXCR7 signal transduction is still under intense study, particularly with respect to mechanisms of signaling specificity.

C-X-C Motif Chemokine Ligand 12 Axis in Tumor Progression

Chemokines and their receptors have long been associated with cancer progression. More recently, the chemokine CXCL12 and its cognate receptors (CXCR4 and CXCR7) have been shown to play central roles in cancer proliferation, angiogenesis, invasion, tumor microenvironment, as well as drug resistance induced by chemotherapy. There appear to be two mechanisms by which CXCL12 affects tumor cell biology: 1) direct stimulation of signaling pathways that promote cancer cell growth, metastasis, and angiogenesis; 2) indirect effects, including the recruitment of CXCR4/CXCR7-positive cancer cells to CXCL12-expressing organs.

C-X-C Motif Chemokine Ligand 12 Axis in Tumor Cell Growth and Survival

One of the major biological effects modulated by the CXCL12 axis is to promote tumor cell survival and proliferation. In 1998, Sehgal et al. first found CXCR4 was overexpressed in glioblastoma cell lines, and the expression of antisense CXCR4 inhibited glioma cell proliferation. Furthermore, exogenous CXCL12 induces proliferation in a dose-dependent manner in human glioblastoma cell lines. The CXCL12 axis has been identified to induce proliferation of cell lines derived from many types of cancers, including prostate cancer, breast cancer, lung cancer, multiple myeloma, and pancreatic cancer. The CXCL12/CXCR4 interaction phosphorylates CXCR4, subsequently promotes calcium flux, and directly activates MAPK, PI3K, Wnt, and Sonic Hedgehog signaling pathways, thus inducing proliferation of various types of tumor cells. The activated MAPK alters translation of mRNA and phosphorylates several other cellular proteins (c-Myc and RSK kinases) that are critical to cell proliferation, cell cycle progression, cell division, and differentiation. CXCR4 expression can be upregulated by the transcription factor c-Myc, which in turn activates MAPK. Therefore, CXCR4 expression and MAPK signaling form a positive feedback loop to further sustain proliferative signaling (Figure 2).

Activation of CXCR4 also increases expression of EGF/EGFR signaling proteins, leading to increased cell proliferation. Wnt signaling plays a pivotal role in CXCL12-induced tumor cell proliferation, as silencing CXCL12/CXCR4 signaling influences pancreatic cancer cell phenotypes and inhibits tumor cell proliferation in vitro via inactivation of the canonical Wnt pathway. Additionally, the activation of AKT and ERK signaling pathways by the CXCL12 axis promotes nuclear accumulation of NFκB and increases NFκB signaling by inducing the phosphorylation and destabilization of IκB-α, followed by SHH up-regulation. Moreover, SHH signaling exerts its paracrine effect mainly by activating protein patched homolog (Ptch) on the surrounding stromal cells and subsequently induces additional CXCL12 expression and extracellular release to complete a positive pro-proliferative feedback loop (Figure 2). CXCR7 activates the AKT signaling pathway and stimulates EGFR signaling, thereby increasing tumor cell proliferation and survival. Moreover, CXCR7 overexpression and gene silencing in tumor cells collectively support the role of CXCR7 contribution to tumor growth. However, study in neuroblastoma (NB) indicated that CXCR7 activation strongly reduced the NB cell growth through ERK1/2 cascade both in vitro and in vivo. Likewise, CXCR7 has been found associated with suppressing tumor growth and migration in colon cancer. These findings reflect a controversial role of CXCR7 in tumor cell proliferation, which also indicates that the function of CXCR7 might be cell type-specific. Extensive studies of its role in different malignancies would be beneficial for achieving precision medicine.

The CXCL12 axis also indirectly exerts anti-apoptotic effects in tumor cells. As mentioned previously, the CXCL12/CXCR4 axis activates AKT and ERK, subsequently leading to NFκB accumulation, which can suppress apoptotic signaling. The induction of MAPK-ERK and PI3K pathways by CXCL12 inactivates the pro-apoptotic BAD (Bcl2-associated agonist of cell death) protein. This may arise through ERK phosphorylation of Bad on serine 112, which results in the dissociation of Bad from Bcl-2 and enables Bcl-2 to exert its anti-apoptotic effects. Similarly, the CXCL12/CXCR4 axis may stimulate ERK phosphorylation of Bim, resulting in Bim dissociation from the anti-apoptotic proteins Bcl-2 and Mcl-1 and enabling the free Bcl-2 and Mcl-1 to exert their anti-apoptotic effects by binding to Bax. CXCR7 signaling also suppresses apoptosis. CXCR7 overexpression reduces the apoptotic fraction in prostate cancer cells and protects these cells from apoptosis. Likewise, knockdown of CXCR7 in the MCF7 breast cancer cell line increased the expression of the pro-apoptotic caspase three and eight proteins.

Another function of the CXCL12 axis in tumor cell growth and survival is evading growth suppression, which is most commonly regulated through the Rb or p53 pathways. Wildtype p53 binds to the GFI-1 binding site in the proximal enhancer region of the CXCR4 gene, which suppresses CXCR4 expression. Treatment with p53 rescue drugs (PRIMA-1, CP- 31398) in p53 mutant cells can restore the suppression of CXCR4 transcription in cells with mutant p53. Loss of functional p53 is commonly observed in many cancer cell lines, which is one of the mechanisms resulting in CXCR4 upregulation. As mentioned before, the CXCL12/CXCR4 axis increases the expression of pro-survival proteins MDM-2 and NFκB through AKT activation. Specifically, MDM-2 phosphorylation of p53 directly leads to its degradation through ubiquitin-dependent proteolysis, thereby promoting tumor cell survival and proliferation.

C-X-C Motif Chemokine Ligand 12 Axis in Angiogenesis

Both in vitro and in vivo studies suggest that the expression level of CXCL12/CXCR4 in cancer cells is positively correlated with microvessel density. Initially, the angiogenic activity of CXCR4 was inferred in mice lacking CXCL12 or CXCR4. For example, mice lacking CXCR4 or CXCL12 are defective in the formation of the large vessels supplying the gastrointestinal tract and exhibit defects in vascular development, hematopoiesis, and cardiogenesis. Moreover, CXCR4 is highly expressed in the endothelial cells of large vessels in tumor stroma, indicating that the CXCL12/CXCR4 signaling plays a vital role in tumor angiogenesis. There are four possible mechanisms by which CXCL12/CXCR4 regulates tumor angiogenesis: 1) upregulates vascular endothelial growth factor (VEGF) expression in tumor tissue through the PI3K/Akt signaling pathway; 2) reduces the expression of glycolytic enzyme phosphoglycerate kinase 1 (PGK1) which suppresses the secretion of VEGF; 3) upregulates several angiogenesis-associated genes in cancer cells; and 4) directs the recruitment of endothelial progenitor cells to the vicinity of neovascularization.

Among various factors involved in tumor angiogenesis, VEGF and its receptor VEGFR play a major role. VEGF can regulate angiogenesis indirectly by inducing endothelial cells to express MMP-2 and MMP-9, thereby enabling chemotaxis of endothelial cells and the formation of capillary channels, and thus indirectly regulate angiogenesis. Moreover, CXCR4/CXCL12 induces AKT phosphorylation, which can upregulate VEGF transcription and protein expression. Under hypoxic conditions, hypoxia-inducible factor 1 (HIF-1) and VEGF increase the expression of CXCR4 in human brain microvascular endothelial cells, which promotes glioblastoma angiogenesis. CXCL12 can induce MMP-2 and MMP-9 upregulation in pancreatic cancer cells. Phosphoglycerate kinase 1 (PGK1) is an ATP-generating glycolytic enzyme that catalyzes the reversible transfer of a phosphate group from 1,3-bisphosphoglycerate (1,3-BPG) to ADP, producing 3-phosphoglycerate (3-PG) and ATP. PGK1 is secreted extracellularly by different types of tumors, acting as a disulfide reductase that serves to cleave plasminogen, thereby generating the tumor blood vessel inhibitor angiostatin. High levels of CXCL12 signaling through CXCR4 reduces PGK1 expression and promote angiogenesis. Another mechanism by which CXCL12 contributes to tumor angiogenesis is through the upregulation of angiogenesis-associated genes, among which IL-6 is the earliest and highest upregulated gene. For example, CXCL12 induces time- and dose-dependent upregulation of IL-6 transcription and protein secretion. This transcriptional regulation of IL-6 by CXCL12 is mediated by phosphorylation of ERK and activation of the NFκB complex. IL-6 induces other angiogenic factors, such as VEGF, basic fibroblast growth factor (bFGF), and COX-2. Endothelial progenitor cells (EPCs) are pluripotent stem cells with the potential to differentiate into mature endothelial cells. Thus, EPCs play a pivotal role in tumor angiogenesis. In a coimplantation xenograft model, carcinoma-associated fibroblasts (CAFs) extracted from human breast carcinomas promoted the growth of admixed breast carcinoma cells by recruiting EPSs into the tumors. Furthermore, CAFs secrete CXCL12 and the recruitment of EPCs is regulated in part by CXCL12. Moreover, CXCR4 is expressed on EPCs, thereby mediating CXCL12 signaling. Finally, the CXCL12/CXCR4 axis increases progesterone-induced EPC viability through the PI3K/AKT pathway. Plasmacytoid dendritic cells (DCs), which induce neoangiogenesis through production of IL-8 and TNF-α, could be attracted to the tumor environment by CXCL12. Extensive CXCR7has been observed in diverse tumor-associated blood vessels and could be upregulated in endothelial cells by hypoxia. The immunohistochemical staining results demonstrated that CXCR7 was widely expressed in human breast and lung cancers, where it was highly expressed on a majority of tumor-associated blood vessels and malignant cells but not expressed on normal vasculature. Downregulation of CXCR7 expression by siRNA resulted in the formation of smaller tumors by these cells. These results are consistent in clinical biopsy samples of ovarian cancer, bladder cancer, kidney cancer, and malignant gliomas. CXCR7 overexpression in murine breast cancer cells promotes tumor development by enhancing angiogenesis. In addition, it was observed in human PCa cells that CXCR7 regulates the expression of the proangiogenic factors interleukin-8 or VEGF, which participates in the regulation of tumor angiogenesis.

C-X-C Motif Chemokine Ligand 12 Axis in Invasion and Metastasis

Metastasis is an important biological characteristic of malignant tumors, which is the key cause of death among cancer patients. Tumor metastasis was once recognized as a passive consequence of a single tumor cell escaping from a primary tumor. However, recent data indicated that tumor metastasis is an active process employing multiple molecular and cellular mechanisms. The CXCL12 axis is also involved in metastasis of many human cancers, such as pancreatic cancer, melanoma, and colon cancer.

In 2001, Muller et al. provided the first evidence that the CXCL12/CXCR4 axis mediates human breast cancer metastasis. For example, a CXCR4 neutralizing antibody and shRNA knockdown of the CXCR4 receptor significantly reduced tumor cell invasion. Moreover, CXCL12 is highly expressed in liver and specifically attracts melanoma and CXCR4 (+) cells, thereby increasing cancer liver metastasis. Upon further study, the CXCL12/CXCR4 axis was shown to regulate metastasis via different mechanisms. Epithelial-to-mesenchymal transition (EMT) has been recognized as an important process that is associated with cancer metastasis. CXCL12/CXCR4 signaling stimulated the SHH signaling pathway, which is associated with EMT and loss of cell adhesion. Moreover, CXCL12/CXCR4 signaling upregulates survivin via the MED/ERK and PI3K/AKT pathways, giving rise to cell cycle progression and EMT in human sacral chondrosarcoma. Analogous findings were observed in glioblastoma and hepatocellular carcinoma. Moreover, CXCL12/CXCR4 signaling stimulates invasion and EMT of colorectal cancer cells through the Wnt/β-catenin signaling pathway. Metalloprotease (MMPs) are a family of enzymes involved in the degradation of extracellular matrix in the surrounding normal tissue with the ability to mediate cancer invasion and metastasis. CXCL12 promotes invasion of bone by myeloma cells by stimulating MMP-9 and MT1-MMP expression. Similarly, CXCR4 promotes the migration and invasion by tongue squamous cell carcinoma cells by stimulating MMP- nine and MMP-13 expression through signaling by the ERK pathway. CXCL12/CXCR4 axis can stimulate the MMP-2 secretion of other types of cells; for example, CXCL12/CXCR4 signaling stimulates the migration of neuroblasts along the corpus callosum. Tumors are often hypoxic, resulting in upregulation of CXCL12 expression in endothelial cells by HIF-1. Therefore, CXCR4-positive cancer stem cells are likely to be attracted to the peripheral vessels, thereby serving as a pool for metastasis. CXCL12 also modulates the expression and function of cell surface integrins, thereby promoting tumor cell adhesion. For example, CXCL12 increases the adhesion of PC- three cells to the human umbilical vein endothelial cell monolayer in a model of tumor extravasation or intravasation. Moreover, CXCL12 stimulates the expression of α5 and β3 integrins by prostate tumor cells, thereby inducing the adhesion of the tumor cells to human endothelium or extracellular matrix. Similarly, CXCL12 induces integrin β1 expression by ovarian tumor cells, leading to increased adhesion of these cells to laminin.

It has been postulated that CXCR7 expression is associated with increased tumor cell adhesion, which provides these tumor cells with a growth and survival advantage. Indeed, overexpression of CXCR7 enhances breast cancer cell adhesion to human umbilical vein endothelial cells (HUVECs). Likewise, increased CXCR7 expression is associated with increased prostate cancer cell aggressiveness; this effect appears to be mediated by cell adhesion proteins CD44 and cadherin-11. Collectively, these data suggest that CXCR7 functions as an oncogene, although much remains to be elucidated, particularly with respect to mechanisms of CXCR7 oncogenic signaling. CXCR7 deficient mice exhibit greater local recurrence of breast cancer following resection, suggesting that CXCR7 may possess breast cancer tumor suppressor activities related to the metastatic cascade. This apparent conundrum may reflect the fact that CXCR7 can heterodimerize with CXCR4 and that loss of CXCR7 may disrupt the balance between oncogenic CXCR4/CXCR7 heterodimers and tumor suppressor homodimers. Clearly, this apparent dichotomy regarding CXCR7 function is yet to be definitively resolved.

C-X-C Motif Chemokine Ligand 12 Axis in Tumor Microenvironment

The importance of the microenvironment to tumor progression is well established. The tumor microenvironment (TME) consists of resident non-cancerous cells (stromal fibroblasts, endothelial cells, and immune cells), proteolytic enzymes, growth factors, inflammatory cytokines, and the extracellular matrix (ECM). CXCL12 regulates tumor-TME interactions, thereby promoting tumor survival, proliferation, angiogenesis, and metastasis.

CXCL12 secreted by carcinoma-associated fibroblasts (CAFs) stimulates tumor growth directly, acting through CXCR4 expressed by breast cancer cells and promoting invasiveness. CXCL12 also functions as a chemoattractant during tumor development. For example, CXCR4-positive cancer cells can be recruited to organs with high expression of CXCL12, including liver, lungs, and bone marrow. CXCR4 activation induces leukemia cell trafficking and homing to the bone marrow microenvironment because of the constitutive secretion of CXCL12 by stromal cells in bone marrow. At the same time, CXCL12 can attract CXCR4-positive inflammatory, vascular, and stromal cells into the tumor mass to support tumor development. This is a major contribution, as CXCR4 is expressed by many cell types in TME, including endothelial cells, epithelial cells, and lymphocytes. It has been suggested that CAFs promote angiogenesis by recruiting endothelial progenitor cells (EPCs) into carcinomas, which is mediated by CXCL12. In vivo studies demonstrated that activation of CXCL12/CXCR4 accelerates the recruitment of fibroblasts and facilitates cancer stromal formation. In a recent study, CXCL12 produced by both the multiple myeloma (MM) cells and bone marrow stromal cells (BMSCs) was found to regulate monocyte migration. And the blockage with anti-CXCR4 antibodies caused significant inhibition of monocyte recruitment. Monocytes differentiate into macrophages that support tumor cell proliferation, angiogenesis, and shape the immunosuppressive microenvironment. Besides, CXCL12 can trigger anti-apoptotic and proliferative signals in colon cancer cells by inducing mononuclear phagocytes to release HB-EGF, which binds the Epidermal Growth Factor Receptor (EGFR/HER1) and stimulates its signaling. In addition, the stroma cells from specialized microenvironments are capable of modulating CXCR4 expression. For example, CFA secretion of transforming growth factor-β (TGF-β) potentiates CXCR4 stimulation of AKT signaling in human prostate epithelial cells, which indicates that synergism between TGF-β, CXCL12, and CXCR4 in tumor stroma contributes to carcinogenesis.

A recent study reported that CXCR7 is highly expressed on a majority of tumor-associated blood vessels. Moreover, CXCR7 expression is upregulated in human microvascular endothelial cells under hypoxic and acidic pH conditions, which are well-known characteristics of the TME. Another work indicates that CXCR7 is also involved in TGF-β induced EMT in lung adenocarcinoma. Furthermore, regulation of the macrophage colony-stimulating factor/macrophage colony-stimulating factor receptor signaling pathway enables CXCR7 to recruit tumor-promoting macrophages to the tumor site. Finally, bone marrow microenvironment is necessary for CXCR7 activation, thereby promoting osteosarcoma invasion. Altogether, these results strongly indicate that CXCR7 modulates cancer survival and metastasis via novel pathways involved in the tumor microenvironment.

Transcriptional Regulation of C-X-C Motif Chemokine Ligand 12 Axis

In addition to the biological effects mediated by CXCL12 axis, investigations are also conducted associated with the transcriptional regulation of CXCL12 axis during cancer progression. Chen et al. reported that c-Myb could elevate CXCL12 expression by activating CXCL12 promoter in breast cancer cells. In pancreatic stellate cells, Galectin-1 was observed to induce CXCL12 secretion by activating NF-κB signaling pathway, thereby increasing pancreatic cancer metastasis. Recent work indicated that c-Myc regulates pancreatic cancer progression via HIF-1α/CXCL12/CXCR4signaling pathway. Knocking down of c-Myc significantly decreased CXCL12 expression and inhibited the invasion of pancreatic cancer cells. Moreover, the activating transcription factor 3 (ATF3) and the c-Jun dimerization protein2 (JDP2) inhibit CXCL12 secretion in tumor-associated fibroblasts in a lung carcinoma murine model. NF-κB is one of the major transcription factors that regulate CXCR4 expression. Further study revealed that elevated levels of NF-κB O-GlcNAcylation promoted CXCR4 expression in cervical cancer cells, thereby increasing lung metastasis. Furthermore, other transcription factors have also been suggested to increase mRNA and protein of CXCR4 in cancer development, including Runt-related transcription factor 2 (RUNX2) and POU1F1transcription factor (Pit-1). Similarly, overexpression of RUNX2 can induce CXCR7 transcription in prostate cancer. Another study demonstrated that CXCR7 expression had been upregulated by interleukin 6 (IL6) that is mainly derived from cancer-associated fibroblasts, contributing to chemoresistance in esophageal squamous cell carcinoma.

C-X-C Motif Chemokine Ligand 12 Axis Promotes Chemoresistance

The CXCL12 axis can contribute to tumor chemoresistance. For example, cancer chemotherapy upregulates CXCL12 and CXCR4 expression in multiple cancers. Moreover, patients who developed distant recurrence of rectal cancers exhibited much higher expression of both CXCR4 and CXCL12 than did patients who did not develop distant recurrence. A more direct evaluation of the role that the CXCL12 axis plays in chemoresistance indicates that the upregulation of CXCR4 in non-small cell lung carcinoma (NSCLC) mediates Gefitinib-resistance associated with EMT. Furthermore, the cancer progenitor population can be maintained by CXCR4 in tamoxifen-resistant breast cancer MCF7 cells by inducing AhR signaling. CXCL12 enhances the resistance of chronic myeloid leukemia to adriamycin (ADM) by stimulating the expression of CXCR4. The mechanism features activation of the downstream PI3K/AKT pathway, translocation of NFκB dimers into the nucleus, and subsequent decrease of the expression of apoptosis-related proteins. Similarly, resistance to ADM can be partially reversed by CXCR4 silencing, and lapatinib-resistant cells exhibit greater CXCR4 expression than parental (sensitive) cells. This chemoresistance is thought to be mediated by Src and CXCR4 signaling, particularly because CXCR4 antibody treatment reduces the invasive ability of cancer cells. Synthetic Exosome-Like Nanoparticles (SELNs) has been demonstrated to evoke apoptosis of human pancreatic cancer. However, further investigation indicated that SELNs induce the activation of NFκB, the expression and secretion of CXCL12, and stimulation of CXCR4/AKT survival pathway, resulting in protection of these tumor cells from death. As mentioned before, CAF-secreted IL-6 stimulates the upregulation of CXCR7 through STAT3/NFκB signaling, promoting resistance of esophageal squamous cell carcinoma cells against cisplatin and 5-FU. Taken together, these findings illustrate the contribution of CXCL12 axis to cancer chemoresistance.

Therapeutic Targeting C-X-C Motif Chemokine Ligand 12 Axis

The CXCL12/CXCR4/CXCR7 axis is a potential target for cancer therapies. Up to now, several molecules have been developed to target CXCL12, CXCR4, or CXCR7. A deep understanding of CXCL12 axis in therapeutic applications would be beneficial for future translation of CXCL12, CXCR4, and CXCR7 inhibitors into clinical use.

Prognostic Marker

Crowther-Swanepoel et al. first reported that functional coding mutations in CXCR4 might contribute to familial chronic lymphocytic leukemia. Similarly, genotyping 466 acute myeloid leukemia patients and 460 healthy controls indicates that a polymorphism in rs2228014 in the CXCR4 coding sequence is significantly increased in AML patients relative to healthy controls. Moreover, CXCL12 and CXCR4 polymorphisms appear to contribute to increased risk of hepatocellular carcinoma (HCC) and may be potential markers for HCC. CXCR4 expression in triple-negative breast cancer (TNBC) cells correlates positively with histopathological grade but negatively with lymph node metastasis. Moreover, heterozygosity for either CXCL12 and CXCR4 variants increases the risk for TNBC by analyzing genetic polymorphisms in 59 TNBC patients and 150 healthy control women. Similarly, it appears that a CXCR4 rs2228014 polymorphism is significantly associated with poor progression-free survival (PFS) in metastatic colorectal cancer patients. Although CXCR4 expression is a prognostic factor in several human tumor types, none of the CXCL12/CXCR4/CXCR7 has yet been definitively validated as a tumor driver. Nonetheless, studies to date indicate that the CXCL12 axis is a tumor promoter rather than a tumor initiator.

Preclinical Studies of Inhibitors

CTCE-9908 is a small peptide CXCL12 analog with CXCR4 antagonist activity. Treatment of osteosarcoma cells in vitro with CTCE-9908 causes decreased adhesion, migration, invasion, and growth rate. These in vitro effects are also observed in vivo, as mice treated with CTCE-19908 exhibit a 50% reduction in lung metastasis caused by tail vein injection of osteosarcoma cells. Similar effects are observed in other types of cancer cells, as CTCE-9908 inhibits ovarian cancer cell migration and induces multinucleation, G2-M arrest, and abnormal mitosis. The anti-tumor and anti-metastatic effects of CTCE-9908 are dramatically enhanced by docetaxel in a breast cancer mouse model system. Another approach for targeting the CXCL12 axis is the CXCL12 PEGylated mirror-image l-oligonucleotide (olaptesed-pegol). In vivo, olaptesed-pegol neutralize CXCL12, leading to a bone marrow microenvironment that is less receptive for multiple myeloma cells and reduces multiple myeloma cell homing and growth. AMD3465 is also a selective small-molecule CXCR4 antagonist that antagonizes CXCL12 stimulation of chemotaxis and prosurvival signaling pathways in leukemia cells. In vivo, subcutaneous injections of BKT140 (a new-generation peptide CXCR4 inhibitor) significantly reduced the growth of human acute myeloid leukemia in a dose-dependent manner. Another CXCR4 antagonist, POL5551, exhibits inhibitory effect on glioblastoma growth and dissemination induced by anti-VEGF therapy.

CCX733 is a selective CXCR7 antagonist that reduces the antiapoptotic effects of CXCL12 in glioma cells and CXCR7-induced EMT in bladder cancer. The CXCR7 antagonists anti-CXCR7-12G8 and CCX771 both inhibit mTOR activation in renal cell carcinoma cells, resulting in reduced metastasis. Similarly, the CXCR7 antagonists CCX754 and CCX771 inhibit lung metastasis of colorectal cancer cells in vivo.

Clinical Application

Plerixafor (AMD3100) is a CXCR4 antagonist that was formally approved by the US FDA in 2008 to use in combination with autologous transplantation in patients with Non-Hodgkin’s Lymphoma or multiple myeloma. By blocking the interaction between CXCL12 and CXCR4, plerixafor triggers the mobilization of stem and progenitor cells (CD34+ cells). These stem cells are then collected and used in autologous stem cell transplantation to rescue the hematopoietic toxicity and to reconstitute hematopoiesis following high-dose chemotherapy. Furthermore, plerixafor injection is used in combination with a granulocyte-colony stimulating factor (G-CSF) medication to prepare the blood for an autologous stem cell transplant. A clinical study involved patients with non-Hodgkin’s lymphoma or multiple myeloma showed the combination of plerixafor and G-CSF was superior to G-CSF alone in mobilizing hematopoietic progenitor cells. Recent clinical trials indicate that plerixafor could be used in other strategies for treating cancer. A phase 1/2 study indicated that the addition of plerixafor to cytotoxic chemotherapy could increase the rates of remission in acute myeloid leukemia. Similarly, the combination of radiochemotherapy (RTCT) and plerixafor yielded a greater delay in tumor growth and lymph node metastasis in patients with cervical cancer than did RTCT alone. Moreover, the combination of plerixafor and bortezomib yielded a strong response rate in relapsed/refractory multiple myeloma. According to the clinical studies, combination with other current cancer therapies would be the primary application of plerixafor or other CXCR4 antagonists. Therefore, pharmacokinetic studies and rational design of dosage are definitely required to avoid potential side effects.

Cancer Immunotherapy

According to the major role of CXCL12 axis in TME, lots of antagonists targeting CXCL12axis were proposed as monotherapy to promote antitumor immunity or in combination with other immunotherapies for cancer treatment. In a mouse model of ovarian cancer, AMD3100 treatment showed significant increases in T-cell–mediated antitumor immune responses, resulting in CXCR4 positive tumor apoptosis and necrosis. Similar results were obtained in multiple cancer models, that AMD3100 administration leads to rapid T cell accumulation and acted synergistically with immunological checkpoint antagonists (anti-PD-L1). AMD3100 also increases the efficiency of the mesothelin-targeted immune-activating fusion protein (VIC-008) in mesothelioma, which is regulated by PD-1suppression in CD8+T cells and conversion of regulatory T into helper-like cells. Another study focused on chemoresistant ovarian cancer reported a novel oncolytic vaccinia virus expressing a CXCR4 antagonist that can reduce the immunosuppressive network and increase tumor apoptosis and phagocytosis alone or in combination with doxorubicin. Genget al. developed a new FAPα-targeted vaccine for the treatment of breast cancer. This DNA vaccine enhanced antigen secretion and effectively decreased the number of CAFs in the TME, leading to decreases in CCL2 and CXCL12 expression, thereby reducing the myeloid-derived suppressor cells in the TME. In glioblastoma, CXCR7-targeted antibody (X7Ab) enhanced tumor cell phagocytosis by increasing macrophages activity. And combining X7Abwith Temozolomide (TMZ) significantly slowed mouse glioma progression with prolonged survival. Cancer immunotherapy targeting CXCL12 axis are giving encouraging results. Further clinical studies based on these findings should be performed to increase the effectiveness of cancer therapy.

Conclusion

Compelling evidence has demonstrated that CXCL12/CXCR4/CXCR7 axis is implicated in tumor growth, survival, angiogenesis, metastasis, tumor microenvironment, and chemoresistance. Thus, the CXCL12 axis is a promising target for therapeutic intervention. However, only a few drugs that target the CXCL12 axis have been approved for clinical use. CXCL12 and its receptors play important roles in homeostasis and non-pathologic inflammation, which might predict that agents that target the CXCL12 axis would possess significant on-target toxicities. Furthermore, crosstalk between CXCR4 and CXCR7 makes specific CXCR4 targeting more challenging. Relatively little is known about the function of CXCR7 and its signal transduction in cancer genesis and/or progression. Elucidating these functions and their mechanisms will undoubtedly contribute to the development of better anticancer agents that target the CXCL12 axis. In clinical applications, the development of targeted drug delivery systems for CXCR4 antagonists should be considered to increase the efficacy of these therapies and to reduce their side effects.

Author Contributions

YS collected the original materials and wrote the first draft. DJR and JS made significant changes on the scope and format of this review.

Funding

This study was supported partially by NIH funding 1R01HL125279-01A1 (JS).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 197

  1. 1.

    Ali A. Kim S. H. Kim M. J. Choi M. Y. Kang S. S. Cho G. J. (2017 ). O-GlcNAcylation of NF-κB promotes lung metastasis of cervical cancer cells via upregulation of CXCR4 expression. Mol Cells 40, 476

    Not in our library10.14348/molcells.2017.2309

  2. 2.

    Ao M. Franco O. E. Park D. Raman D. Williams K. Hayward S. W. (2007 ). Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Canc. Res. 67, 4244–4253.

    Not in our library10.1158/0008-5472.can-06-3946

  3. 3.

    Avraham S. Korin B. Aviram S. Shechter D. Shaked Y. Aronheim A. (2019 ). Atf3 and jdp2 deficiency in cancer associated fibroblasts promotes tumor growth via sdf-1 transcription. Oncogene 38, 3812–3823.

    Not in our library10.1038/s41388-019-0692-y

  4. 4.

    Bachelerie F. Graham G. J. Locati M. Mantovani A. Murphy P. M. Nibbs R. (2014 ). New nomenclature for atypical chemokine receptors. Nat. Immunol. 15, 207–208.

    Not in our library10.1038/ni.2812

  5. 5.

    Bagri A. Gurney T. He X. Zou Y. R. Littman D. R. Tessier-Lavigne M. (2002 ). The chemokine SDF1 regulates migration of dentate granule cells. Development 129, 4249–4260.

    Not in our library10.1242/dev.129.18.4249

  6. 6.

    Bai Y. Yang Y. Yan Y. Zhong J. Blee A. M. Pan Y. (2019 ). RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis. Theranostics 9, 3459

    Not in our library10.7150/thno.33292

  7. 7.

    Bajetto A. Bonavia R. Barbero S. Florio T. Schettini G. (2001 ). Chemokines and their receptors in the central nervous system. Front. Neuroendocrinol. 22, 147–184.

    Not in our library10.1006/frne.2001.0214

  8. 8.

    Balabanian K. Lagane B. Infantino S. Chow K. Y. Harriague J. Moepps B. (2005 ). The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J. Biol. Chem. 280, 35760–35766.

    Not in our library10.1074/jbc.m508234200

  9. 9.

    Barbero S. Bonavia R. Bajetto A. Porcile C. Pirani P. Ravetti J. L. (2003 ). Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Canc. Res. 63, 1969–1974

    Not in our library

  10. 10.

    Barbieri F. Bajetto A. Florio T. (2010 ). Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target. J. Oncol. 2010, 426956

    Not in our library10.1155/2010/426956

  11. 11.

    Barcellos-Hoff M. H. Ravani S. A. (2000 ). Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Canc. Res. 60, 1254–1260

    Not in our library

  12. 12.

    Bartolomé R. A. Ferreiro S. Miquilena-Colina M. E. Martínez-Prats L. Soto-Montenegro M. L. García-Bernal D. (2009 ). The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs. Am. J. Pathol. 174, 602–612.

    Not in our library10.2353/ajpath.2009.080636

  13. 13.

    Beider K. Begin M. Abraham M. Wald H. Weiss I. D. Wald O. (2011 ). CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp. Hematol. 39, 282–292.

    Not in our library10.1016/j.exphem.2010.11.010

  14. 14.
    Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype · 2014
    No notice
  15. 15.

    Beloribi-Djefaflia S. Siret C. Lombardo D. (2015 ). Exosomal lipids induce human pancreatic tumoral MiaPaCa-2 cells resistance through the CXCR4-SDF-1α signaling axis. Oncoscience 2, 15

    Not in our library10.18632/oncoscience.96

  16. 16.

    Bernhagen J. Krohn R. Lue H. Gregory J. L. Zernecke A. Koenen R. R. (2007 ). MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 13, 587–596.

    Not in our library10.1038/nm1567

  17. 17.

    Bhowmick N. A. Chytil A. Plieth D. Gorska A. E. Dumont N. Shappell S. (2004 ). TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848–851.

    Not in our library10.1126/science.1090922

  18. 18.

    Bosco M. C. Puppo M. Santangelo C. Anfosso L. Pfeffer U. Fardin P. (2006 ). Hypoxia modifies the transcriptome of primary human monocytes: modulation of novel immune-related genes and identification of CC-chemokine ligand 20 as a new hypoxia-inducible gene. J. Immunol. 177, 1941–1955.

    Not in our library10.4049/jimmunol.177.3.1941

  19. 19.

    Burger J. A. Kipps T. J. (2006 ). CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107, 1761–1767.

    Not in our library10.1182/blood-2005-08-3182

  20. 20.

    Burger J. A. Peled A. (2009 ). CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 23, 43–52.

    Not in our library10.1038/leu.2008.299

  21. 21.

    Burns J. M. Summers B. C. Wang Y. Melikian A. Berahovich R. Miao Z. (2006 ). A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 203, 2201–2213.

    Not in our library10.1084/jem.20052144

  22. 22.

    Busillo J. M. Benovic J. L. (2007 ). Regulation of CXCR4 signaling. Biochim. Biophys. Acta 1768, 952–963.

    Not in our library10.1016/j.bbamem.2006.11.002

  23. 23.

    Carmeliet P. (2005 ). VEGF as a key mediator of angiogenesis in cancer. Oncology 69 (Suppl 3), 4–10.

    Not in our library10.1159/000088478

  24. 24.

    Chambers A. F. Groom A. C. MacDonald I. C. (2002 ). Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Canc. 2, 563–572.

    Not in our library10.1038/nrc865

  25. 25.

    Chang C. C. Chen S. C. Hsieh Y. H. Chen Y. C. Chen T. Y. Chu Y. H. (2009 ). Stromal cell-derived factor-1 but not its receptor, CXCR4, gene variants increase susceptibility and pathological development of hepatocellular carcinoma. Clin. Chem. Lab. Med. 47, 412–418.

    Not in our library10.1515/cclm.2009.092

  26. 26.

    Chaudary N. Pintilie M. Jelveh S. Lindsay P. Hill R. P. Milosevic M. (2017 ).Plerixafor improves primary tumor response and reduces metastases in cervical cancer treated with radio-chemotherapy. Clin. Canc. Res. 23, 1242–1249.

    Not in our library10.1158/1078-0432.ccr-16-1730

  27. 27.

    Chen G. Gharib T. G. Wang H. Huang C. C. Kuick R. Thomas D. G. (2003 ). Protein profiles associated with survival in lung adenocarcinoma. Proc. Natl. Acad. Sci. U.S.A. 100, 13537–13542.

    Not in our library10.1073/pnas.2233850100

  28. 28.

    Chen L. Xu S. Zeng X. Li J. Yin W. Chen Y. (2010 ). c-myb activates cxcl12 transcription in t47d and mcf7 breast cancer cells. Acta Biochim. Biophys. Sin. 42, 1–7.

    Not in our library10.1093/abbs/gmp108

  29. 29.

    Chen Y. Ramjiawan R. R. Reiberger T. Ng M. R. Hato T. Huang Y. (2015 ). CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology 61, 1591–1602.

    Not in our library10.1002/hep.27665

  30. 30.

    Chu C.-Y. Cha S.-T. Lin W.-C. Lu P.-H. Tan C.-T. Chang C.-C. (2009 ). Stromal cell- derived factor-1α (SDF-1α/CXCL12)-enhanced angiogenesis of human basal cell carcinoma cells involves ERK1/2–NF-κB/interleukin-6 pathway. Carcinogenesis 30, 205–213.

    Not in our library10.1093/carcin/bgn228

  31. 31.

    Crowther-Swanepoel D. Qureshi M. Dyer M. J. Matutes E. Dearden C. Catovsky D. (2009 ). Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia. Blood 114, 4843–4846.

    Not in our library10.1182/blood-2009-07-235184

  32. 32.

    Curiel T. J. Cheng P. Mottram P. Alvarez X. Moons L. Evdemon-Hogan M. (2004 ). Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Canc. Res. 64, 5535–5538.

    Not in our library10.1158/0008-5472.can-04-1272

  33. 33.

    Daly E. B. Wind T. Jiang X. M. Sun L. Hogg P. J. (2004 ). Secretion of phosphoglycerate kinase from tumour cells is controlled by oxygen-sensing hydroxylases. Biochim. Biophys. Acta 1691, 17–22.

    Not in our library10.1016/j.bbamcr.2003.11.004

  34. 34.

    De Clercq E. (2019 ).Mozobil® (plerixafor, AMD3100), 10 years after its approval by the US food and drug administration. Antivir. Chem. Chemother. 27, 2040206619829382

    Not in our library10.1177/2040206619829382

  35. 35.

    De Falco V. Guarino V. Avilla E. Castellone M. D. Salerno P. Salvatore G. (2007 ). Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Canc. Res. 67, 11821–11829.

    Not in our library10.1158/0008-5472.can-07-0899

  36. 36.

    De Luca A. D’Alessio A. Gallo M. Maiello M. Bode A. Normanno N. (2014 ). Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib. Cell Cycle 13, 148–156.

    Not in our library10.4161/cc.26899

  37. 37.

    DiPersio J. F. Uy G. L. Yasothan U. Kirkpatrick P. (2009 ). Plerixafor [Dataset].

    Not in our library10.1038/nrd2819

  38. 38.

    Dubrovska A. Hartung A. Bouchez L. Walker J. Reddy V. Cho C. (2012 ). CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br. J. Canc. 107, 43–52.

    Not in our library10.1038/bjc.2012.105

  39. 39.

    Duda D. G. Kozin S. V. Kirkpatrick N. D. Xu L. Fukumura D. Jain R. K. (2011 ). CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin. Canc. Res. 17, 2074–2080.

    Not in our library10.1158/1078-0432.ccr-10-2636

  40. 40.

    Egeblad M. Werb Z. (2002 ). New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Canc. 2, 161–174.

    Not in our library10.1038/nrc745

  41. 41.

    Engl T. Relja B. Marian D. Blumenberg C. Müller I. Beecken W. D. (2006 ). CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia 8, 290

    Not in our library10.1593/neo.05694

  42. 42.

    Feig C. Jones J. O. Kraman M. Wells R. J. Deonarine A. Chan D. S. (2013 ). Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. U.S.A. 110, 20212–20217.

    Not in our library10.1073/pnas.1320318110

  43. 43.

    Feng Y. Broder C. C. Kennedy P. E. Berger E. A. (1996 ). HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872–877.

    Not in our library10.1126/science.272.5263.872

  44. 44.

    Fernandis A. Z. Cherla R. P. Chernock R. D. Ganju R. K. (2002 ). CXCR4/CCR5 down-modulation and chemotaxis are regulated by the proteasome pathway. J. Biol. Chem. 277, 18111–18117.

    Not in our library10.1074/jbc.m200750200

  45. 45.

    Flomenberg N. Devine S. M. DiPersio J. F. Liesveld J. L. McCarty J. M. Rowley S. D. (2005 ). The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 106, 1867–1874.

    Not in our library10.1182/blood-2005-02-0468

  46. 46.

    Gagner J. P. Sarfraz Y. Ortenzi V. Alotaibi F. M. Chiriboga L. A. Tayyib A. T. (2017 ). Multifaceted C-X-C chemokine receptor 4 (CXCR4) inhibition interferes with anti-vascular endothelial growth factor therapy-induced glioma dissemination. Am. J. Pathol. 187, 2080–2094.

    Not in our library10.1016/j.ajpath.2017.04.020

  47. 47.

    Gangadhar T. Nandi S. Salgia R. (2010 ). The role of chemokine receptor CXCR4 in lung cancer. Canc. Biol. Ther. 9, 409–416.

    Not in our library10.4161/cbt.9.6.11233

  48. 48.

    Ganju R. K. Brubaker S. A. Meyer J. Dutt P. Yang Y. Qin S. (1998 ). The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J. Biol. Chem. 273, 23169–23175.

    Not in our library10.1074/jbc.273.36.23169

  49. 49.

    Gao W. Mei X. Wang J. Zhang X. Yuan Y. (2015 ). ShRNA-mediated knock-down of CXCR7 increases TRAIL-sensitivity in MCF-7 breast cancer cells. Tumour Biol. 36, 7243–7250.

    Not in our library10.1007/s13277-015-3432-0

  50. 50.

    Gao Z. Wang X. Wu K. Zhao Y. Hu G. (2010 ). Pancreatic stellate cells increase the invasion of human pancreatic cancer cells through the stromal cell-derived factor-1/CXCR4 axis. Pancreatology 10, 186–193.

    Not in our library10.1159/000236012

  51. 51.

    Geng F. Guo J. Guo Q. Q. Xie Y. Dong L. Zhou Y. (2019 ). A DNA vaccine expressing an optimized secreted FAPα induces enhanced anti-tumor activity by altering the tumor microenvironment in a murine model of breast cancer. Vaccine 37, 4382–4391.

    Not in our library10.1016/j.vaccine.2019.06.012

  52. 52.

    Gerits N. Kostenko S. Shiryaev A. Johannessen M. Moens U. (2008 ). Relations between the mitogen-activated protein kinase and the cAMP-dependent protein kinase pathways: comradeship and hostility. Cell. Signal. 20, 1592–1607.

    Not in our library10.1016/j.cellsig.2008.02.022

  53. 53.

    Getts D. R. Terry R. L. Getts M. T. Deffrasnes C. Müller M. van Vreden C. (2014 ). Therapeutic inflammatory monocyte modulation using immune-modifying microparticles. Sci. Transl. Med. 6, 219ra7

    Not in our library10.1126/scitranslmed.3007563

  54. 54.

    Ghanem I. Riveiro M. E. Paradis V. Faivre S. de Parga P. M. Raymond E. (2014 ). Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis. Am J Transl Res 6, 340–352

    Not in our library

  55. 55.

    Ghobrial I. M. Liu C. J. Zavidij O. Azab A. K. Baz R. Laubach J. P. (2019 ). Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am. J. Hematol. 94, 1244–1253.

    Not in our library10.1002/ajh.25627

  56. 56.

    Goldsmith Z. Dhanasekaran D. (2007 ). G protein regulation of MAPK networks. Oncogene 26, 3122–3142.

    Not in our library10.1038/sj.onc.1210407

  57. 57.

    Gravel S. Malouf C. Boulais P. E. Berchiche Y. A. Oishi S. Fujii N. (2010 ). The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains. J. Biol. Chem. 285, 37939–37943.

    Not in our library10.1074/jbc.c110.147470

  58. 58.

    Griffith J. W. Sokol C. L. Luster A. D. (2014 ). Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu. Rev. Immunol. 32, 659–702.

    Not in our library10.1146/annurev-immunol-032713-120145

  59. 59.

    Guembarovski A. L. Guembarovski R. L. Hirata B. K. B. Vitiello G. A. F. Suzuki K. M. Enokida M. T. (2018 ). CXCL12 chemokine and CXCR4 receptor: association with susceptibility and prognostic markers in triple negative breast cancer. Mol. Biol. Rep. 45, 741–750.

    Not in our library10.1007/s11033-018-4215-7

  60. 60.

    Guillemot E. Karimdjee-Soilihi B. Pradelli E. Benchetrit M. Goguet-Surmenian E. Millet M. (2012 ). CXCR7 receptors facilitate the progression of colon carcinoma within lung not within liver. Br. J. Canc. 107, 1944–1949.

    Not in our library10.1038/bjc.2012.503

  61. 61.

    Guo Z. J. Yang L. Qian F. Wang Y. X. Yu X. Ji C. D. (2016 ). Transcription factor runx2 up-regulates chemokine receptor cxcr4 to promote invasive and metastatic potentials of human gastric cancer. Oncotarget 7, 20999

    Not in our library10.18632/oncotarget.8236

  62. 62.

    Gupta S. K. Lysko P. G. Pillarisetti K. Ohlstein E. Stadel J. M. (1998 ). Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J. Biol. Chem. 273, 4282–4287.

    Not in our library10.1074/jbc.273.7.4282

  63. 63.

    Han Y. Wu C. Wang J. Liu N. (2017 ). Cxcr7 maintains osteosarcoma invasion after cxcr4 suppression in bone marrow microenvironment. Tumour Biol. 39, 1010428317701631

    Not in our library10.1177/1010428317701631

  64. 64.

    Hao M. Zheng J. Hou K. Wang J. Chen X. Lu X. (2012 ). Role of chemokine receptor CXCR7 in bladder cancer progression. Biochem. Pharmacol. 84, 204–214.

    Not in our library10.1016/j.bcp.2012.04.007

  65. 65.

    Hassan S. Buchanan M. Jahan K. Aguilar-Mahecha A. Gaboury L. Muller W. J. (2011 ). CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int. J. Canc. 129, 225–232.

    Not in our library10.1002/ijc.25665

  66. 66.

    Hattermann K. Held-Feindt J. Lucius R. Müerköster S. S. Penfold M. E. Schall T. J. (2010 ). The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Canc. Res. 70, 3299–3308.

    Not in our library10.1158/0008-5472.can-09-3642

  67. 67.

    Hayashi H. Kume T. (2008 ). Forkhead transcription factors regulate expression of the chemokine receptor CXCR4 in endothelial cells and CXCL12-induced cell migration. Biochem. Biophys. Res. Commun. 367, 584–589.

    Not in our library10.1016/j.bbrc.2007.12.183

  68. 68.

    Heckmann D. Maier P. Laufs S. Li L. Sleeman J. P. Trunk M. J. (2014 ). The disparate twins: a comparative study of CXCR4 and CXCR7 in SDF-1α-induced gene expression, invasion and chemosensitivity of colon cancer. Clin. Canc. Res. 20, 604–616.

    Not in our library10.1158/1078-0432.ccr-13-0582

  69. 69.
    Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis · 2011
    No notice
  70. 70.

    Hirata H. Hinoda Y. Kikuno N. Kawamoto K. Dahiya A. V. Suehiro Y. (2007 ). CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin. Canc. Res. 13, 5056–5062.

    Not in our library10.1158/1078-0432.ccr-07-0859

  71. 71.

    Horgan K. Jones D. Mansel R. (1987 ). Mitogenicity of human fibroblasts in vivo for human breast cancer cells. Br. J. Surg. 74, 227–229.

    Not in our library10.1002/bjs.1800740326

  72. 72.

    Hu T. H. Yao Y. Yu S. Han L. L. Wang W. J. Guo H. (2014 ). SDF-1/CXCR4 promotes epithelial-mesenchymal transition and progression of colorectal cancer by activation of the Wnt/β-catenin signaling pathway. Canc. Lett. 354, 417–426.

    Not in our library10.1016/j.canlet.2014.08.012

  73. 73.

    Hu Y. Zang J. Qin X. Yan D. Cao H. Zhou L. (2017 ). Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin. OncoTargets Ther. 10, 2341

    Not in our library10.2147/ott.s124757

  74. 74.

    Hwang T. L. Liang Y. Chien K. Y. Yu J. S. (2006 ). Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics 6, 2259–2272.

    Not in our library10.1002/pmic.200500345

  75. 75.

    Ieranò C. Santagata S. Napolitano M. Guardia F. Grimaldi A. Antignani E. (2014 ). CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells. Cell Death Dis. 5, e1310

    Not in our library10.1038/cddis.2014.269

  76. 76.

    Imai H. Sunaga N. Shimizu Y. Kakegawa S. Shimizu K. Sano T. (2010 ). Clinicopathological and therapeutic significance of CXCL12 expression in lung cancer. Int. J. Immunopathol. Pharmacol. 23, 153–164.

    Not in our library10.1177/039463201002300114

  77. 77.

    Ishigami S. Natsugoe S. Okumura H. Matsumoto M. Nakajo A. Uenosono Y. (2007 ). Clinical implication of CXCL12 expression in gastric cancer. Ann. Surg Oncol. 14, 3154–3158.

    Not in our library10.1245/s10434-007-9521-6

  78. 78.

    Janssens R. Struyf S. Proost P. (2018 ). Pathological roles of the homeostatic chemokine CXCL12. Cytokine Growth Factor Rev. 44, 51–68.

    Not in our library10.1016/j.cytogfr.2018.10.004

  79. 79.

    Jee S. H. Chu C. Y. Chiu H. C. Huang Y. L. Tsai W. L. Liao Y. H. (2004 ). Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J. Invest. Dermatol. 123, 1169–1175.

    Not in our library10.1111/j.0022-202x.2004.23497.x

  80. 80.

    Jiang Y. Ma W. Wan Y. Kozasa T. Hattori S. Huang X. Y. (1998 ). The G protein G alpha12 stimulates Bruton’s tyrosine kinase and a rasGAP through a conserved PH/BM domain. Nature 395, 808

    Not in our library10.1038/27454

  81. 81.

    Jiang Y. P. Wu X. H. Shi B. Wu W. X. Yin G. R. (2006 ). Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol. Oncol. 103, 226–233.

    Not in our library10.1016/j.ygyno.2006.02.036

  82. 82.
    Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer · 2005
    No notice
  83. 83.

    Katoh H. Hosono K. Ito Y. Suzuki T. Ogawa Y. Kubo H. (2010 ). COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems. Am. J. Pathol. 176, 1469–1483.

    Not in our library10.2353/ajpath.2010.090607

  84. 84.

    Katoh M. Katoh M. (2010 ). Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFbeta, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors. Int. J. Oncol. 36, 415–420.

    Not in our library10.3892/ijo_00000514

  85. 85.

    Kijima T. Maulik G. Ma P. C. Tibaldi E. V. Turner R. E. Rollins B. (2002 ). Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-kit in small cell lung cancer cells. Canc. Res. 62, 6304–6311.

    Not in our library

  86. 86.

    Kim J. Mori T. Chen S. L. Amersi F. F. Martinez S. R. Kuo C. (2006 ). Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann. Surg. 244, 113

    Not in our library10.1097/01.sla.0000217690.65909.9c

  87. 87.

    Kim S. Y. Lee C. H. Midura B. V. Yeung C. Mendoza A. Hong S. H. (2008 ). Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin. Exp. Metastasis 25, 201–211.

    Not in our library10.1007/s10585-007-9133-3

  88. 88.

    Kioi M. Vogel H. Schultz G. Hoffman R. M. Harsh G. R. Brown J. M. (2010 ). Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 120, 694–705.

    Not in our library10.1172/jci40283

  89. 89.

    Klein K. R. Karpinich N. O. Espenschied S. T. Willcockson H. H. Dunworth W. P. Hoopes S. L. (2014 ). Decoy receptor CXCR7 modulates adrenomedullin-mediated cardiac and lymphatic vascular development. Dev. Cell 30, 528–540.

    Not in our library10.1016/j.devcel.2014.07.012

  90. 90.

    Komorowski M. P. McGray A. R. Kolakowska A. Eng K. Gil M. Opyrchal M. (2016 ). Reprogramming antitumor immunity against chemoresistant ovarian cancer by a cxcr4 antagonist-armed viral oncotherapy. Mol Ther Oncolytics 3, 16034

    Not in our library10.1038/mto.2016.34

  91. 91.

    Konopleva M. Y. Jordan C. T. (2011 ). Leukemia stem cells and microenvironment: biology and therapeutic targeting. J. Clin. Oncol. 29, 591

    Not in our library10.1200/jco.2010.31.0904

  92. 92.

    Krohn A. Song Y. H. Muehlberg F. Droll L. Beckmann C. Alt E. (2009 ). CXCR4 receptor positive spheroid forming cells are responsible for tumor invasion in vitro. Canc. Lett. 280, 65–71.

    Not in our library10.1016/j.canlet.2009.02.005

  93. 93.

    Kucia M. Reca R. Miekus K. Wanzeck J. Wojakowski W. Janowska-Wieczorek A. (2005 ). Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem cells 23, 879–894.

    Not in our library10.1634/stemcells.2004-0342

  94. 94.

    Kufareva I. Salanga C. L. Handel T. M. (2015 ). Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies. Immunol. Cell Biol. 93, 372–383.

    Not in our library10.1038/icb.2015.15

  95. 95.

    Kukreja P. Abdel-Mageed A. B. Mondal D. Liu K. Agrawal K. C. (2005 ). Up- regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1α (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway–dependent NF-κB activation. Canc. Res. 65, 9891–9898.

    Not in our library10.1158/0008-5472.can-05-1293

  96. 96.

    Kwong J. Kulbe H. Wong D. Chakravarty P. Balkwill F. (2009 ). An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Mol. Canc. Therapeut. 8, 1893–1905.

    Not in our library10.1158/1535-7163.mct-08-0966

  97. 97.

    Lafleur M. A. Handsley M. M. Edwards D. R. (2003 ). Metalloproteinases and their inhibitors in angiogenesis. Expet Rev. Mol. Med. 5, 1–39.

    Not in our library10.1017/s1462399403006628

  98. 98.

    Levoye A. Balabanian K. Baleux F. Bachelerie F. Lagane B. (2009 ). CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 113, 6085–6093.

    Not in our library10.1182/blood-2008-12-196618

  99. 99.

    Li B. Zeng Y. Reeves P. M. Ran C. Liu Q. Qu X. (2018 ). Amd3100 augments the efficacy of mesothelin-targeted, immune-activating vic-008 in mesothelioma by modulating intratumoral immunosuppression. Cancer Immunol Res. 6, 539–551.

    Not in our library10.1158/2326-6066.cir-17-0530

  100. 100.

    Li H. Yang L. Fu H. Yan J. Wang Y. Guo H. (2013 ). Association between Gαi2 and ELMO1/Dock180 connects chemokine signalling with Rac activation and metastasis. Nat. Commun. 4, 1706–1712.

    Not in our library10.1038/ncomms2680

  101. 101.

    Li X. Li P. Chang Y. Xu Q. Wu Z. Ma Q. (2014 ).The SDF-1/CXCR4 axis induces epithelial–mesenchymal transition in hepatocellular carcinoma. Mol. Cell. Biochem. 392, 77–84.

    Not in our library10.1007/s11010-014-2020-8

  102. 102.

    Li X. Ma Q. Xu Q. Liu H. Lei J. Duan W. (2012 ). SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway. Canc. Lett. 322, 169–176.

    Not in our library10.1016/j.canlet.2012.02.035

  103. 103.

    Liang Z. Brooks J. Willard M. Liang K. Yoon Y. Kang S. (2007 ). CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem. Biophys. Res. Commun. 359, 716–722.

    Not in our library10.1016/j.bbrc.2007.05.182

  104. 104.

    Liao A. Shi R. Jiang Y. Tian S. Li P. Song F. (2016 ). SDF-1/CXCR4 Axis regulates cell cycle progression and epithelial-mesenchymal transition via up-regulation of survivin in glioblastoma. Mol. Neurobiol. 53, 210–215.

    Not in our library10.1007/s12035-014-9006-0

  105. 105.

    Liberman J. Sartelet H. Flahaut M. Mühlethaler-Mottet A. Coulon A. Nyalendo C. (2012 ). Involvement of the cxcr7/cxcr4/cxcl12 axis in the malignant progression of human neuroblastoma. PLoS One 7, e43665,

    Not in our library10.1371/journal.pone.0043665

  106. 106.

    Libert F. Parmentier M. Lefort A. Dinsart C. Van Sande J. Maenhaut C. (1989 ). Selective amplification and cloning of four new members of the G protein-coupled receptor family. Science 244, 569–572.

    Not in our library10.1126/science.2541503

  107. 107.

    Liu X. Zhou Y. Peng J. Xie B. Shou Q. Wang J. (2020 ). Silencing c-myc enhances the antitumor activity of bufalin by suppressing the HIF-1α/SDF-1/CXCR4 pathway in pancreatic cancer cells. Front. Pharmacol. 11, 495

    Not in our library10.3389/fphar.2020.00495

  108. 108.

    Liu Z. Teng X. Y. Meng X. P. Wang B. S. (2014 ). Expression of stromal cell-derived factor 1 and CXCR7 ligand receptor system in pancreatic adenocarcinoma. World J. Surg. Oncol. 12, 348

    Not in our library10.1186/1477-7819-12-348

  109. 109.

    Luker K. E. Gupta M. Luker G. D. (2009 ). Imaging chemokine receptor dimerization with firefly luciferase complementation. FASEB. J. 23, 823–834.

    Not in our library10.1096/fj.08-116749

  110. 110.

    Luther S. A. Bidgol A. Hargreaves D. C. Schmidt A. Xu Y. Paniyadi J. (2002 ). Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J. Immunol. 169, 424–433.

    Not in our library10.4049/jimmunol.169.1.424

  111. 111.

    Luttrell L. M. Gesty-Palmer D. (2010 ). Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol. Rev. 62, 305–330.

    Not in our library10.1124/pr.109.002436

  112. 112.

    Lv S. Yang Y. Kwon S. Han M. Zhao F. Kang H. (2014 ). The association of CXCR4 expression with prognosis and clinicopathological indicators in colorectal carcinoma patients: a meta-analysis. Histopathology 64, 701–712.

    Not in our library10.1111/his.12321

  113. 113.

    Ma W. Liu Y. Ellison N. Shen J. (2013 ).Induction of C-X-C chemokine receptor type 7 (CXCR7) switches stromal cell-derived factor-1 (SDF-1) signaling and phagocytic activity in macrophages linked to atherosclerosis. J. Biol. Chem. 288, 15481–15494.

    Not in our library10.1074/jbc.m112.445510

  114. 114.

    Madden S. L. Cook B. P. Nacht M. Weber W. D. Callahan M. R. Jiang Y. (2004 ). Vascular gene expression in nonneoplastic and malignant brain. Am. J. Pathol. 165, 601–608.

    Not in our library10.1016/s0002-9440(10)63324-x

  115. 115.

    Mao W. Yi X. Qin J. Tian M. Jin G. (2016 ). CXCL12/CXCR4 axis improves migration of neuroblasts along corpus callosum by stimulating MMP-2 secretion after traumatic brain injury in rats. Neurochem. Res. 41, 1315–1322.

    Not in our library10.1007/s11064-016-1831-2

  116. 116.

    Marchesi F. Monti P. Leone B. E. Zerbi A. Vecchi A. Piemonti L. (2004 ). Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Canc. Res. 64, 8420–8427.

    Not in our library10.1158/0008-5472.can-04-1343

  117. 117.

    Martinez-Ordoñez A. Seoane S. Cabezas P. Eiro N. Sendon-Lago J. Macia M. (2018 ). Breast cancer metastasis to liver and lung is facilitated by pit-1-cxcl12-cxcr4 axis. Oncogene 37, 1430–1444.

    Not in our library10.1038/s41388-017-0036-8

  118. 118.

    Matsusaka S. Cao S. Hanna D. Sunakawa Y. Ueno M. Mizunuma N. (2017 ). CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy. Pharmacogenomics J. 17, 543–550.

    Not in our library10.1038/tpj.2016.59

  119. 119.

    McCubrey J. A. Steelman L. S. Chappell W. H. Abrams S. L. Wong E. W. Chang F. (2007 ). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 1773, 1263–1284.

    Not in our library10.1016/j.bbamcr.2006.10.001

  120. 120.

    McLatchie L. M. Fraser N. J. Main M. J. Wise A. Brown J. Thompson N. (1998 ). RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393, 333–339.

    Not in our library10.1038/30666

  121. 121.

    Meijer J. Ogink J. Roos E. (2008 ). Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo. Br. J. Canc. 99, 1493–1501.

    Not in our library10.1038/sj.bjc.6604727

  122. 122.

    Mellado M. Rodríguez-Frade J. M. Vila-Coro A. J. Fernández S. Martín de Ana A. Jones D. R. (2001 ). Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO J. 20, 2497–2507.

    Not in our library10.1093/emboj/20.10.2497

  123. 123.

    Miao Z. Luker K. E. Summers B. C. Berahovich R. Bhojani M. S. Rehemtulla A. (2007 ). CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc. Natl. Acad. Sci. U.S.A. 104, 15735–15740.

    Not in our library10.1073/pnas.0610444104

  124. 124.

    Monnier J. Boissan M. L’Helgoualc’h A. Lacombe M. L. Turlin B. Zucman-Rossi J. (2012 ). CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells. Eur. J. Canc. 48, 138–148.

    Not in our library10.1016/j.ejca.2011.06.044

  125. 125.

    Müller A. Homey B. Soto H. Ge N. Catron D. Buchanan M. E. (2001 ). Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50–56.

    Not in our library10.1038/35065016

  126. 126.
    CXCR7 Functions as a Scavenger for CXCL12 and CXCL11 · 2010
    No notice
  127. 127.
    Systematic classification of vertebrate chemokines based on conserved synteny and evolutionary history · 2012
    No notice
  128. 128.

    Odemis V. Lipfert J. Kraft R. Hajek P. Abraham G. Hattermann K. (2012 ). The presumed atypical chemokine receptor CXCR7 signals through G(i/o) proteins in primary rodent astrocytes and human glioma cells. Glia 60, 372–381.

    Not in our library10.1002/glia.22271

  129. 129.

    Orimo A. Gupta P. B. Sgroi D. C. Arenzana-Seisdedos F. Delaunay T. Naeem R. (2005 ). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335–348.

    Not in our library10.1016/j.cell.2005.02.034

  130. 130.

    Pan F. Ma S. Cao W. Liu H. Chen F. Chen X. (2013 ). SDF-1α upregulation of MMP-2 is mediated by p38 MAPK signaling in pancreatic cancer cell lines. Mol. Biol. Rep. 40, 4139–4146.

    Not in our library10.1007/s11033-012-2225-4

  131. 131.
    Stromal Derived Factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis · 2006
    No notice
  132. 132.

    Parmo-Cabañas M. Molina-Ortiz I. Matías-Román S. García-Bernal D. Carvajal-Vergara X. Valle I. (2006 ). Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes. J. Pathol. 208, 108–118.

    Not in our library10.1002/path.1876

  133. 133.

    Princen K. Hatse S. Vermeire K. De Clercq E. Schols D. (2003 ). Evaluation of SDF-1/CXCR4-induced Ca2+ signaling by fluorometric imaging plate reader (FLIPR) and flow cytometry. Cytometry 51, 35–45.

    Not in our library10.1002/cyto.a.10008

  134. 134.

    Qian D. Lu Z. Xu Q. Wu P. Tian L. Zhao L. (2017 ). Galectin-1-driven upregulation of sdf-1 in pancreatic stellate cells promotes pancreatic cancer metastasis. Canc. Lett. 397, 43–51.

    Not in our library10.1016/j.canlet.2017.03.024

  135. 135.

    Qiao N. Wang L. Wang T. Li H. (2016 ). Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells. Tumour Biol. 37, 8169–8179.

    Not in our library10.1007/s13277-015-4686-2

  136. 136.

    Qiao Y. Zhang C. Li A. Wang D. Luo Z. Ping Y. (2018 ). IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma. Oncogene 37, 873–883.

    Not in our library10.1038/onc.2017.387

  137. 137.

    Qin G. Chen Y. Li H. Xu S. Li Y. Sun J. (2016 ). Melittin inhibits tumor angiogenesis modulated by endothelial progenitor cells associated with the SDF-1α/CXCR4 signaling pathway in a UMR-106 osteosarcoma xenograft mouse model. Mol. Med. Rep. 14, 57–68.

    Not in our library10.3892/mmr.2016.5215

  138. 138.

    Qin L. F. Qin J. M. Zhang J. Q. Lv X. P. Huang L. Y. Wang J. J. (2018 ). CXCL12 and CXCR4 polymorphisms and expressions in peripheral blood from patients of hepatocellular carcinoma. Future Oncol. 14, 1261–1271.

    Not in our library10.2217/fon-2017-0613

  139. 139.

    Ratajczak M. Zuba-Surma E. Kucia M. Reca R. Wojakowski W. Ratajczak J. (2006 ). The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 20, 1915–1924.

    Not in our library10.1038/sj.leu.2404357

  140. 140.

    Righi E. Kashiwagi S. Yuan J. Santosuosso M. Leblanc P. Ingraham R. (2011 ). Cxcl12/cxcr4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Canc. Res. 71, 5522–5534.

    Not in our library10.1158/0008-5472.can-10-3143

  141. 141.

    Rigo A. Gottardi M. Zamò A. Mauri P. Bonifacio M. Krampera M. (2010 ). Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. Mol. Canc. 9, 273

    Not in our library10.1186/1476-4598-9-273

  142. 142.

    Roccaro A. M. Sacco A. Purschke W. G. Moschetta M. Buchner K. Maasch C. (2014 ). SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Rep. 9, 118–128.

    Not in our library10.1016/j.celrep.2014.08.042

  143. 143.

    Rollins B. J. (1997 ). Chemokines. Blood 90, 909–928.

    Not in our library10.1182/blood.v90.3.909

  144. 144.

    Romagnani P. Lasagni L. Annunziato F. Serio M. Romagnani S. (2004 ). CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol. 25, 201–209.

    Not in our library10.1016/j.it.2004.02.006

  145. 145.

    Rot A. Von Andrian U. H. (2004 ). Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 22, 891–928.

    Not in our library10.1146/annurev.immunol.22.012703.104543

  146. 146.

    Rubin J. B. (2009 ). Chemokine signaling in cancer: one hump or two? Semin. Canc. Biol. 19, 116–122.

    Not in our library10.1016/j.semcancer.2008.10.001

  147. 147.

    Saigusa S. Toiyama Y. Tanaka K. Yokoe T. Okugawa Y. Kawamoto A. (2010 ). Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy. Ann. Surg Oncol. 17, 2051–2058.

    Not in our library10.1245/s10434-010-0970-y

  148. 148.

    Saini V. Staren D. M. Ziarek J. J. Nashaat Z. N. Campbell E. M. Volkman B. F. (2011 ). The CXC chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor-1α function through distinct receptor interactions. J. Biol. Chem. 286, 33466–33477.

    Not in our library10.1074/jbc.m111.233742

  149. 149.

    Sakai N. Yoshidome H. Shida T. Kimura F. Shimizu H. Ohtsuka M. (2012 ). CXCR4/CXCL12 expression profile is associated with tumor microenvironment and clinical outcome of liver metastases of colorectal cancer. Clin. Exp. Metastasis 29, 101–110.

    Not in our library10.1007/s10585-011-9433-5

  150. 150.

    Salazar N. Carlson J. C. Huang K. Zheng Y. Oderup C. Gross J. (2018 ). A chimeric antibody against ackr3/cxcr7 in combination with tmz activates immune responses and extends survival in mouse gbm models. Mol. Ther. 26, 1354–1365.

    Not in our library10.1016/j.ymthe.2018.02.030

  151. 151.

    Sánchez-Martín L. Estecha A. Samaniego R. Sánchez-Ramón S. Vega M. Á. Sánchez-Mateos P. (2011 ). The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood 117, 88–97.

    Not in our library10.1182/blood-2009-12-258186

  152. 152.

    Scheid M. P. Schubert K. M. Duronio V. (1999 ). Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase. J. Biol. Chem. 274, 31108–31113.

    Not in our library10.1074/jbc.274.43.31108

  153. 153.

    Scotton C. J. Wilson J. L. Scott K. Stamp G. Wilbanks G. D. Fricker S. (2002 ). Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Canc. Res. 62, 5930–5938

    Not in our library

  154. 154.

    Sehgal A. Keener C. Boynton A. L. Warrick J. Murphy G. P. (1998 ). CXCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. J. Surg. Oncol. 69, 99–104.

    Not in our library10.1002/(sici)1096-9098(199810)69:2<99::aid-jso10>3.0.co;2-m

  155. 155.

    Shaked Y. Henke E. Roodhart J. M. Mancuso P. Langenberg M. H. Colleoni M. (2008 ). Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Canc. Cell 14, 263–273.

    Not in our library10.1016/j.ccr.2008.08.001

  156. 156.

    Shen X. Wang S. Wang H. Liang M. Xiao L. Wang Z. (2009 ). The role of SDF-1/CXCR4 axis in ovarian cancer metastasis. J. Huazhong Univ. Sci. Technol.—Med. Sci. 29, 363–367.

    Not in our library10.1007/s11596-009-0320-0

  157. 157.

    Sierro F. Biben C. Martínez-Muñoz L. Mellado M. Ransohoff R. M. Li M. (2007 ). Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc. Natl. Acad. Sci. U.S.A. 104, 14759–14764.

    Not in our library10.1073/pnas.0702229104

  158. 158.

    Singh A. P. Arora S. Bhardwaj A. Srivastava S. K. Kadakia M. P. Wang B. (2012 ). CXCL12/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated activation of nuclear factor κB: implications for bidirectional tumor-stromal interactions. J. Biol. Chem. 287, 39115–39124.

    Not in our library10.1074/jbc.m112.409581

  159. 159.

    Singh R. K. Lokeshwar B. L. (2011 ). The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Canc. Res. 71, 3268–3277.

    Not in our library10.1158/0008-5472.can-10-2769

  160. 160.

    Sleightholm R. L. Neilsen B. K. Li J. Steele M. M. Singh R. K. Hollingsworth M. A. (2017 ). Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy. Pharmacol. Ther. 179, 158–170.

    Not in our library10.1016/j.pharmthera.2017.05.012

  161. 161.

    Spill F. Reynolds D. S. Kamm R. D. Zaman M. H. (2016 ). Impact of the physical microenvironment on tumor progression and metastasis. Curr. Opin. Biotechnol. 40, 41–48.

    Not in our library10.1016/j.copbio.2016.02.007

  162. 162.

    Sreedharan S. P. Robichon A. Peterson K. E. Goetzl E. J. (1991 ). Cloning and expression of the human vasoactive intestinal peptide receptor. Proc. Natl. Acad. Sci. U.S.A. 88, 4986–4990.

    Not in our library10.1073/pnas.88.11.4986

  163. 163.

    Stacer A. C. Fenner J. Cavnar S. P. Xiao A. Zhao S. Chang S. L. (2016 ). Endothelial CXCR7 regulates breast cancer metastasis. Oncogene 35, 1716–1724.

    Not in our library10.1038/onc.2015.236

  164. 164.

    Sun Y. Cheng Z. Ma L. Pei G. (2002 ). Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J. Biol. Chem. 277, 49212–49219.

    Not in our library10.1074/jbc.m207294200

  165. 165.

    Suzuki Y. Rahman M. Mitsuya H. (2001 ). Diverse transcriptional response of CD4+ T cells to stromal cell-derived factor SDF-1: cell survival promotion and priming effects of SDF-1 on CD4+ T cells. J. Immunol. 167, 3064–3073.

    Not in our library10.4049/jimmunol.167.6.3064

  166. 166.

    Tachibana K. Hirota S. Iizasa H. Yoshida H. Kawabata K. Kataoka Y. (1998 ). The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393, 591–594.

    Not in our library10.1038/31261

  167. 167.

    Tanaka T. Bai Z. Srinoulprasert Y. Yang B. Yang B. Hayasaka H. (2005 ). Chemokines in tumor progression and metastasis. Canc. Sci. 96, 317–322.

    Not in our library10.1111/j.1349-7006.2005.00059.x

  168. 168.
    Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis · 2016
    No notice
  169. 169.

    Thomas R. M. Kim J. Revelo-Penafiel M. P. Angel R. Dawson D. W. Lowy A. M. (2008 ). The chemokine receptor CXCR4 is expressed in pancreatic intraepithelial neoplasia. Gut 57, 1555–1560.

    Not in our library10.1136/gut.2007.143941

  170. 170.

    Ueda Y. Neel N. F. Schutyser E. Raman D. Richmond A. (2006 ). Deletion of the COOH-terminal domain of CXC chemokine receptor 4 leads to the down-regulation of cell-to-cell contact, enhanced motility and proliferation in breast carcinoma cells. Canc. Res. 66, 5665–5675.

    Not in our library10.1158/0008-5472.can-05-3579

  171. 171.

    Uy G. L. Rettig M. P. Motabi I. H. McFarland K. Trinkaus K. M. Hladnik L. M. (2012 ). A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 119, 3917–3924.

    Not in our library10.1182/blood-2011-10-383406

  172. 172.

    Vicari A. P. Caux C. (2002 ). Chemokines in cancer. Cytokine Growth Factor Rev. 13, 143–154.

    Not in our library10.1016/s1359-6101(01)00033-8

  173. 173.
    CXCR7 Targeting and Its Major Disease Relevance · 2018
    Not checked
  174. 174.

    Wang J. Shiozawa Y. Wang J. Wang Y. Jung Y. Pienta K. J. (2008a ). The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J. Biol. Chem. 283, 4283–4294.

    Not in our library10.1074/jbc.m707465200

  175. 175.

    Wang J. Wang J. Dai J. Jung Y. Wei C. L. Wang Y. (2007 ). A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Canc. Res. 67, 149–159.

    Not in our library10.1158/0008-5472.can-06-2971

  176. 176.

    Wang J. F. Park I. W. Groopman J. E. (2000 ). Stromal cell-derived factor-1alpha stimulates tyrosine phosphorylation of multiple focal adhesion proteins and induces migration of hematopoietic progenitor cells: roles of phosphoinositide-3 kinase and protein kinase C. Blood 95, 2505–2513.

    Not in our library10.1182/blood.v95.8.2505

  177. 177.

    Wang W. Liu D. Yang L. Li Y. Xu H. Wang F. (2016 ). CXCR4 overexpression correlates with poor prognosis in myasthenia gravis-associated thymoma. Hum. Pathol. 49, 49–53.

    Not in our library10.1016/j.humpath.2015.10.007

  178. 178.

    Wang Y. Miao H. Li W. Yao J. Sun Y. Li Z. (2014 ). CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells. Biochem. Pharmacol. 90, 212–225.

    Not in our library10.1016/j.bcp.2014.05.007

  179. 179.

    Wang Z. Ma Q. Liu Q. Yu H. Zhao L. Shen S. (2008b ). Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway. Br. J. Canc. 99, 1695–1703.

    Not in our library10.1038/sj.bjc.6604745

  180. 180.

    Wani N. Nasser M. W. Ahirwar D. K. Zhao H. Miao Z. Shilo K. (2014 ). C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment. Breast Cancer Res. 16, R54

    Not in our library10.1186/bcr3665

  181. 181.

    Ward S. G. (2006 ). T lymphocytes on the move: chemokines, PI 3-kinase and beyond. Trends Immunol. 27, 80–87.

    Not in our library10.1016/j.it.2005.12.004

  182. 182.

    Weekes C. D. Song D. Arcaroli J. Wilson L. A. Rubio-Viqueira B. Cusatis G. (2012 ). Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer. Neoplasia 14, 690

    Not in our library10.1593/neo.111810

  183. 183.

    Wu B. Chien E. Y. Mol C. D. Fenalti G. Liu W. Katritch V. (2010 ). Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066–1071.

    Not in our library10.1126/science.1194396

  184. 184.

    Wu Y. Tang S. Sun G. Sun K. (2016 ). CXCR7 mediates TGFβ1-promoted EMT and tumor-initiating features in lung cancer. Oncogene 35, 2123–2132.

    Not in our library10.1038/onc.2015.274

  185. 185.

    Würth R. Bajetto A. Harrison J. K. Barbieri F. Florio T. (2014 ). CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment. Front. Cell. Neurosci. 8, 144

    Not in our library10.3389/fncel.2014.00144

  186. 186.

    Yang D. Xin M. Wang J. Xu H. Huo Q. Tang Z. (2015a ). Chemokine receptor CXCR4 and its ligand CXCL12 expressions and clinical significance in bladder cancer. Genet. Mol. Res. 14, 17699–17707.

    Not in our library10.4238/2015.december.21.43

  187. 187.

    Yang M. Zeng C. Li P. Qian L. Ding B. Huang L. (2019 ). Impact of CXCR4 and CXCR7 knockout by CRISPR/Cas9 on the function of triple-negative breast cancer cells. OncoTargets Ther. 12, 3849

    Not in our library10.2147/ott.s195661

  188. 188.

    Yang P. Wang G. Huo H. Li Q. Zhao Y. Liu Y. (2015b ). SDF-1/CXCR4 signaling up-regulates survivin to regulate human sacral chondrosarcoma cell cycle and epithelial-mesenchymal transition via ERK and PI3K/AKT pathway. Med. Oncol. 32, 377

    Not in our library10.1007/s12032-014-0377-x

  189. 189.

    Yu P. Zhang Z. Li S. Wen X. Quan W. Tian Q. (2016 ). Progesterone modulates endothelial progenitor cell (EPC) viability through the CXCL12/CXCR4/PI3K/Akt signalling pathway. Cell Prolif. 49, 48–57.

    Not in our library10.1111/cpr.12231

  190. 190.

    Yu T. Wu Y. Helman J. I. Wen Y. Wang C. Li L. (2011 ).CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway. Mol. Canc. Res. 9, 161–172.

    Not in our library10.1158/1541-7786.mcr-10-0386

  191. 191.

    Zabel B. A. Wang Y. Lewén S. Berahovich R. D. Penfold M. E. Zhang P. (2009 ). Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J. Immunol. 183, 3204–3211.

    Not in our library10.4049/jimmunol.0900269

  192. 192.

    Zagzag D. Lukyanov Y. Lan L. Ali M. A. Esencay M. Mendez O. (2006 ). Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab. Invest. 86, 1221–1232.

    Not in our library10.1038/labinvest.3700482

  193. 193.

    Zeelenberg I. S. Ruuls-Van Stalle L. Roos E. (2003 ). The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Canc. Res. 63, 3833–3839

    Not in our library

  194. 194.

    Zeng Z. Shi Y. Samudio I. J. Wang R. Y. Ling X. Frolova O. (2009 ). Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113, 6215–6224.

    Not in our library10.1182/blood-2008-05-158311

  195. 195.

    Zhang S. Qi L. Li M. Zhang D. Xu S. Wang N. (2008 ). Chemokine CXCL12 and its receptor CXCR4 expression are associated with perineural invasion of prostate cancer. J. Exp. Clin. Canc. Res. 27, 62

    Not in our library10.1186/1756-9966-27-62

  196. 196.

    Zheng Q. Shuai X. Ye Y. Jin Y. Jiang N. Chen X. (2016 ). The role of polymorphisms of stromal-derived factor-1 and CXC receptor 4 in acute myeloid leukemia and leukemia cell dissemination. Gene 588, 103–108.

    Not in our library10.1016/j.gene.2016.04.059

  197. 197.

    Zhi Y. Lu H. Duan Y. Sun W. Guan G. Dong Q. (2015 ). Involvement of the nuclear factor-κB signaling pathway in the regulation of CXC chemokine receptor-4 expression in neuroblastoma cells induced by tumor necrosis factor-α. Int. J. Mol. Med. 35, 349–357.

    Not in our library10.3892/ijmm.2014.2032

Cited by papers we hold 5

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.